Recently, Benli Technology officially obtained the ‘Pharmaceutical Production License’ issued by China’s National Medical Products Administration (NMPA), marking its formal entry into the pharmaceutical manufacturing sector. Originally a high-tech enterprise focused on fine chemicals and pharmaceutical intermediates, this license represents a critical milestone in the company’s strategic shift toward vertical integration—extending its business downstream from active pharmaceutical ingredients (APIs) to finished drug formulations.In China, the Pharmaceutical Production License is a mandatory credential for legal drug manufacturing, requiring rigorous evaluation across multiple dimensions, including quality management systems, production facilities, personnel qualifications, and regulatory compliance. Benli Technology’s successful approval demonstrates its mature implementation of Good Manufacturing Practice (GMP) standards and reflects strong regulatory confidence in its production capabilities and quality control.Looking ahead, Benli is well-positioned to leverage its existing technical expertise and manufacturing capacity to accelerate development in high-value segments such as advanced drug formulations and specialty generics. This strategic move is expected to enhance the company’s competitiveness in the healthcare sector and strengthen its ability to expand into both domestic and international markets, as well as integrate into the global pharmaceutical supply chain.
近日，本立科技（Benli Technology）正式取得国家药品监督管理局颁发的《药品生产许可证》，标志着该公司正式进入药品生产领域。作为一家原本专注于精细化工和医药中间体研发与制造的高新技术企业，此次获得药品生产资质，是其向产业链下游延伸、实现从‘原料药’到‘制剂’一体化战略转型的重要里程碑。《药品生产许可证》是中国药品生产企业合法开展药品生产活动的必要资质，其审批过程严格，涵盖质量管理体系、生产设施、人员资质及合规性等多个维度。本立科技顺利通过审核，不仅体现了其在GMP（药品生产质量管理规范）体系建设方面的成熟度，也彰显了监管部门对其生产能力和质量控制水平的高度认可。未来，本立科技有望依托现有技术优势和产能基础，加速布局高端制剂、特色仿制药等高附加值产品线，进一步提升公司在医药健康领域的综合竞争力。此举也将为其拓展国内外市场、参与全球医药供应链提供有力支撑。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/7931.html